Surrey Heartlands

Joint Formulary & PAD

Perampanel - Epilepsy

You are here : Home > Formulary Search > Perampanel - Epilepsy

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Restrictions / Comments :

Documentation

Guidelines (National)
Generic anti-epileptic drugs -Use in epilepsy - updated January 2014
Safety Information
MHRA alert - Anti-epileptics switching between products - updated November 2017
Information
Epilepsy in pregnancy - Royal College ObGyn Guidelines Jun16.pdf

PAD Profile

ChemicalSubstance :
Perampanel
Indication :
Epilepsy
Group Name :
Keywords :
Brand Names Include :
Fycompa
Important Information :
Requires specialist initiation and supply for at least 12 weeks prior to a transfer of care to primary care prescribers
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3

Other Indications

Below are listed other indications that Perampanel is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Epilepsy.

Committee Recommendations (2)

05 Jun 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a change in traffic light status for Perampanel.

Perampanel for treatment in all licensed indications will be given a BLUE (with specialist initiation and supply for at least 12 weeks) traffic light status. 
 

04 Apr 18 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The PCN supported the principles of switching from brand to generic medications (not recommended in the elderly) as per national guidelines in September 2013 and the proposed place in therapy of the anti-epileptic drugs which is based on NICE guidance was also discussed at that time. Transfer of care documents supported in March 2015 are attached below. Please note the MHRA categorisations for each drug in the attached guidance (updated January 2014) and in the link below.